You are here

  • Home
  • Archive
  • Volume 4, Issue 2
  • Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study

Citation Tools

Article menu

Download PDFPDF

Rheumatoid arthritis
Original article
Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Matucci-Cerinic M, Allanore Y, Kavanaugh A, et al
Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study
RMD Open 2018;4:e000757. doi: 10.1136/rmdopen-2018-000757